Rolapitant
In Stock•Starting at $145 for 10 mg•Purity ≥ 99%
| CAS No. | 552292-08-7 |
|---|---|
| MDL No. | MFCD23105917 |
| MF | C25H26F6N2O2 |
| MW | 500.50 |
| InChI Key | FIVSJYGQAIEMOC-ZGNKEGEESA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| 10 mg | 99% | $145 | In Stock | |
| 25 mg | 99% | $255 | In Stock | |
| 50 mg | 99% | $380 | In Stock | |
| 100 mg | 99% | $527 | In Stock | |
| 250 mg | 99% | $789 | In Stock |
Product Information
Rolapitant is an azaspiro compound, specifically 1,7-diazaspiro[4.5]decan-2-one, with additional phenyl and 1-{[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl groups at position 8. It is used as the hydrochloride hydrate for the prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy. It functions as an antiemetic and neurokinin-1 receptor antagonist. It is an ether, azaspiro compound, pyrrolidin-2-one, piperidine, and organofluorine compound. It is the conjugate base of rolapitant(1+).
| CAS No. | 552292-08-7 |
|---|---|
| Product Name | Rolapitant |
Biological Targets
TACR1
Associated Conditions
Chemotherapy-induced nausea and vomiting·post operative nausea and vomiting·Nausea·sarcoma·Vomiting
* The information provided here is compiled from public sources and is for reference only.
